Seattle Genetics Inc's market capitalization of $28,721,622,063 is ahead of 93.35% of US-listed equities.
SGEN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 713.26 -- higher than 94.46% of US-listed equities with positive expected earnings growth.
With a price/sales ratio of 28.28, Seattle Genetics Inc has a higher such ratio than 93.94% of stocks in our set.
If you're looking for stocks that are quantitatively similar to Seattle Genetics Inc, a group of peers worth examining would be NVCN, STRO, FOLD, CLVS, and EDIT.
Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. The company was founded in 1998 and is based in Bothell, Washington.
BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the second quarter and six months ended June 30, 2020. The Company also highlighted ADCETRIS (brentuximab vedotin), PADCEV (enfortumab vedotin-ejfv) and TUKYSA (tucatinib) commercial and development accomplishments, as well as progress with its lead pipeline programs to treat cancer. “We generated record product sales of $240.5 million in the second quarter driven by ADCETRIS, PADCEV and n
We have forgotten that curing cancer starts with preventing cancer in the first place. – David Agus Seattle Genetics (SGEN) is an efficiently-managed and ambitious company that specializes in the research and development of special cancer-cells-targeting drugs based on antibody–drug conjugate (ADC) technology, which harnesses the targeting ability of monoclonal...
Michael A. Gayed, CFA on Seeking Alpha | July 29, 2020